Loading...
XETR
SRT
Market cap13bUSD
Apr 04, Last price  
151.60EUR
1D
-5.25%
1Q
-11.45%
Jan 2017
111.38%
Name

Sartorius AG

Chart & Performance

D1W1MN
P/E
147.77
P/S
3.67
EPS
1.03
Div Yield, %
0.48%
Shrs. gr., 5y
-12.93%
Rev. gr., 5y
13.10%
Revenues
3.38b
-0.44%
484,301,000521,053,000589,027,000611,621,000602,084,000659,317,000733,100,000845,710,000887,269,000891,168,0001,114,752,0001,300,296,0001,404,570,0001,566,034,0001,826,966,0002,335,657,0003,449,222,0004,174,700,0003,395,700,0003,380,700,000
Net income
84m
-59.06%
22,026,00029,019,00030,132,00016,282,000975,00031,020,00052,795,00048,510,00052,424,00048,524,000126,303,000102,932,000114,730,000141,342,000218,743,000321,472,000426,978,000913,100,000205,200,00084,000,000
CFO
976m
+14.36%
43,852,00051,715,00033,141,00052,990,000143,364,00096,008,00079,034,00053,163,000103,260,000129,688,000125,362,000170,421,000206,509,000244,524,000377,189,000511,525,000865,814,000734,200,000853,600,000976,200,000
Dividend
Apr 02, 20240.73 EUR/sh
Earnings
Apr 16, 2025

Profile

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
URL
https://www.sartorius.com/
IPO date
Apr 01, 1999
Employees
15,048
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,380,700
-0.44%
3,395,700
-18.66%
4,174,700
21.03%
Cost of revenue
2,937,100
2,848,100
2,985,100
Unusual Expense (Income)
NOPBT
443,600
547,600
1,189,600
NOPBT Margin
13.12%
16.13%
28.50%
Operating Taxes
49,400
95,900
268,600
Tax Rate
11.14%
17.51%
22.58%
NOPAT
394,200
451,700
921,000
Net income
84,000
-59.06%
205,200
-77.53%
913,100
113.85%
Dividends
(50,700)
(98,200)
(85,900)
Dividend yield
0.86%
0.54%
0.38%
Proceeds from repurchase of equity
198,300
BB yield
-3.36%
Debt
Debt current
393,100
288,000
555,000
Long-term debt
4,347,900
5,170,500
2,129,800
Deferred revenue
Other long-term liabilities
188,600
192,100
294,100
Net debt
3,845,500
4,949,500
2,368,000
Cash flow
Cash from operating activities
976,200
853,600
734,200
CAPEX
(409,900)
(559,700)
(522,600)
Cash from investing activities
(425,800)
(2,823,300)
(1,129,900)
Cash from financing activities
(128,300)
2,165,700
209,900
FCF
471,500
(108,500)
159,840
Balance
Cash
828,700
394,200
196,800
Long term investments
66,800
114,800
120,000
Excess cash
726,465
339,215
108,065
Stockholders' equity
1,202,000
2,712,200
2,614,300
Invested Capital
7,919,735
7,921,585
5,111,935
ROIC
4.98%
6.93%
20.57%
ROCE
4.90%
6.28%
21.81%
EV
Common stock shares outstanding
34,231
68,416
68,416
Price
172.40
-34.57%
263.50
-21.23%
334.50
-32.70%
Market cap
5,901,348
-67.26%
18,027,580
-21.23%
22,885,106
-32.70%
EV
10,879,848
23,667,180
25,922,206
EBITDA
859,500
889,900
1,476,700
EV/EBITDA
12.66
26.60
17.55
Interest
184,100
185,400
35,200
Interest/NOPBT
41.50%
33.86%
2.96%